注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Vincerx Pharma Inc是一家臨床階段的生命科學公司,專注於開發和腫瘤學知識,以推進新療法,以解決癌症治療方面未滿足的醫療需求。該公司的小分子藥物計劃包括VIP152,這是一種選擇性的、臨床階段的陽性轉錄延伸因子-β/細胞週期蛋白依賴性激酶9(PTEFb/CDK9)抑製劑。該公司的抗體藥物偶聯物(ADC)平台包括VIP943和VIP924,它們是針對已知和腫瘤目標的ADC化合物。生物偶聯計劃還包括VIP236,它是一種用於實體瘤的小分子藥物偶聯物(SMDC)。它的SMDC平台針對具有優化喜樹鹼的晚期實體瘤,喜樹鹼是一種強效細胞毒素(彈頭、有效載荷或弓形蟲)。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Laura I. Bushnell | 54 | 2020 | Independent Director |
Francisco D. Salva | 52 | 2020 | Independent Director |
Howard A. Burris | - | 2021 | Member of Scientific Advisory Board |
Brian J. Druker | 67 | 2020 | Independent Director |
John H. Lee | 55 | 2020 | Independent Director |
John C. Byrd | - | 2021 | Founder & Chairman of Scientific Advisory Board |
Anthony W. Tolcher | - | 2021 | Member of Scientific Advisory Board |
Ruth E. Stevens | 64 | 2021 | Independent Director |
Andre Goy | - | 2021 | Member of Scientific Advisory Board |
Apostolia Tsimberidou | - | 2024 | Member of Scientific Advisory Board |
Naval G. Daver | - | 2024 | Member of Scientific Advisory Board |
Ian W. Flinn | - | 2021 | Member of Scientific Advisory Board |
Alice Mims | - | 2024 | Member of Scientific Advisory Board |
Marina Konopleva | - | 2024 | Member of Scientific Advisory Board |
Uma Borate | - | 2024 | Member of Scientific Advisory Board |
Amer Zeidan | - | 2024 | Member of Scientific Advisory Board |
Raquel E. Izumi | 54 | 2020 | Co-Founder, President, COO, Secretary & Director |
Ahmed M. Hamdy | 59 | 2020 | Co-Founder, Chairman & CEO |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核